BazireS: Cytochrome P450 drug metabolism. In: Psychotropic Drug Directory 2014: The Professionals' Pocket Handbook and Aide Memoire. Edited by BazireS. Dorsington, Warwickshire (UK), Lloyd-Reinhold Communications LLP, 2014, pp. 429–433.
2.
CabaleiroT, OchoaD, López-RodriguezR, RománM, NovalbosJ, AyusoC, Abad-SantosF: Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone on healthy volunteers. Hum Psychopharmacol, 29:459–469, 2014.
3.
Dos Santos-JúniorA, HenriquesTB, de MelloMP, Della TorreOH, PaesLA, Ferreira-NetoAP, SewaybrickerLE, FontanaTS, CeleriEH, Guerra-JúniorG, DalgalarrondoP: Pharmacogenetics of risperidone and cardiovascular risk in children and adolescents. Int J Endocrinol, 2016:5872423, 2016.
4.
Dos Santos JúniorA, HenriquesTB, de MelloMP, Ferreira NetoAP, PaesLA, Della TorreOH, SewaybrickerLE, FontanaTS, CeleriEH, Guerra JúniorG, DalgalarrondoP: Hyperprolactinemia in children and adolescents with use of risperidone: Clinical and molecular genetics aspects. J Child Adolesc Psychopharmacol, 25:738–748, 2015.
5.
KhoranaN, MaphantaS, LohitnavyO, SrichaiyaA, SayasathidJ: Comparative pharmacokinetics and bioequivalence of two tablet formulations of 2 mg risperidone in healthy Thai male volunteers. Int J Clin Pharmacol Ther, 49:409–414, 2011.
6.
WhitneyZ, BoydaHN, ProcyshynRM, ElbeD, BlackT, EslamiA, BarrAM: Therapeutic drug levels of second generation antipsychotics in youth: A systematic review. J Child Adolesc Psychopharmacol, 25:234–245, 2015.